Truvestments Capital LLC bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,396 shares of the biopharmaceutical company’s stock, valued at approximately $114,000.
Several other hedge funds have also recently bought and sold shares of the business. Capital Financial Planning LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $28,000. Well Done LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth $30,000. Riverview Trust Co purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $33,000. Trust Department MB Financial Bank N A purchased a new stake in Bristol-Myers Squibb in the 1st quarter worth $32,000. Finally, Portfolio Solutions LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $37,000. Hedge funds and other institutional investors own 74.09% of the company’s stock.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 17th. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target for the company. in a research note on Monday. Finally, Bank of America cut their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $56.88.
Shares of NYSE:BMY traded up $0.31 during trading on Wednesday, reaching $47.74. The company’s stock had a trading volume of 8,758,808 shares, compared to its average volume of 18,652,727. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 12 month low of $44.30 and a 12 month high of $63.69. The company has a market cap of $77.58 billion, a price-to-earnings ratio of 11.99, a PEG ratio of 2.19 and a beta of 0.77.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter last year, the firm earned $0.94 EPS. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, equities analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.44%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
In other news, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the transaction, the insider now directly owns 3,066 shares of the company’s stock, valued at $145,818.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Theodore R. Samuels II bought 5,000 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were bought at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the transaction, the director now owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. 0.12% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Truvestments Capital LLC Invests $114,000 in Bristol-Myers Squibb Co (BMY)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://sundanceherald.com/2019/05/22/truvestments-capital-llc-takes-114000-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.